SABAF

Earnings Review

BUY ord. (Unchanged) Target: € 22.00 (Unchanged) Risk: High

STOCKDATA			ORD	
Price (as of 17 May 2024)			19.1	
Bloomberg Code			SAB IM	
Market Cap (€ mn)			237	
Free Float			46%	
Shares Out (mn)			12.4	
52 week Range		€ 13	3.3 - 19.1	
Daily Volume			4,996	
Performance (%)	1M	3M	1Y	
Absolute	10.8	14.1	19.1	
Rel to FTSE Italia All-Share	5.3	2.5	-7.2	
MAIN METRICS	2023	2024E	2025E	
SALES Adj	238	274	291	
EBITDA Adj	33.1	44.1	51.5	
EBIT Adj	17.5	22.9	29.7	
NET INCOME Adj	14.2	14.5	18.5	
EPS Adj - €c	119	116	149	
DPS Ord - €c	54.0	55.0	56.0	
MULTIPLES	2023	2024E	2025E	
P/E ord Adj	14.6x	16.4x		
EV/EBITDA Adj	8.9x	6.9x	5.7x	
EV/EBIT Adj	16.8x	13.3x	9.9x	
	10.07	13.58	J.J.	
REMUNERATION	2023	2024E	2025E	
Div. Yield ord (A)	3.4%	2.9%	2.9%	
FCF Yield Adj	9.2%	6.9%	7.5%	
INDEBTEDNESS	2023	2024E	2025E	
NFP Adj	-73.2	-63.6	-52.5	
D/Ebitda Adj	2.2x	1.4x	1.0x	
by contaid may	L.LA	1.77	1.07	

PRICE ORD LAST 365 DAYS



Analyst: Domenico Ghilotti d.ghilotti@equita.eu I +39 02 6204.249

POSITIVE ORGANIC SALES AND 300BPS OF MARGIN EXPANSION

1Q24 was the second quarter in a row of positive YoY organic top-line performance (+7.2%) and margin expansion (+300bps) and the first quarter since the start of the market downturn beating our expectations in terms of profitability. We expect next quarters to consolidate this path, given supportive messages on orders in 2Q24 and growing contribution from company-specific drivers (ramp-up of Mexican and Indian plants, MEC/PGA integration, entry in induction) in 2H24. We confirm our estimates and our BUY rating on the stock, trading at 10x EV/EBIT and 13x Adj PE 2025.

1Q24 results: +7.2% organic sales, +300bps in EBITDA margin

Sabaf (SAB) 1Q24 was the second quarter in a row of positive organic top-line performance and YoY margin expansion (though not yet at the medium-term high-teens target) and was the first quarter since the start of the market downturn delivering a positive surprise on our expectations in terms of profitability. In more detail:

- Sales grew by +19% to € 68.9mn vs. € 69.1mn exp., with organic +7.2% vs. 7.0% expected and M&A adding € 6.5mn vs. € 7.0mn expected;
- Adj. EBITDA jumped by +48% to € 10.6mn vs. € 10.1mn expected. Margin reached 15.3% (excluding hyperinflation impact, but including start-up costs, no more booked as one-off costs as done in 2023) vs. 14.6% expected and +300bps vs. 12.3% in 1Q23 (+360bps if we include start-up costs in 1Q23 normalized EBITDA, as done in 1Q24);
- Adj NI more than trebled to € 4.6mn, benefitting from higher EBITDA, lower D&A, FX gains and lower tax rate;
- **NFP** € -77.1mn, in line with expectations, with € **3.9mn cash absorption in 1Q24** due to NWC absorption (higher receivables on lower factoring utilization vs. December).

2024 outlook confirmed, well supported by current trading

In the call **management commented orders in 2Q as "brilliant"**, providing comfort on 2024 outlook. Visibility on 2H24 is limited, as usual, but management indicated that 2Q24 will see sequential organic top-line growth and there are no reasons to expect a deterioration of organic performance in 2H, also considering the growing contribution from Mexico (and to a lower extent India and induction).

Overall, **the tone of the call was very supportive**, with 2Q expected to accelerate vs. 1Q (we were expecting a flattish sequential performance) and message on orders just qualitative but very reassuring.

Too early to revise estimates but visibility on 2024 projections highly improved

The indication on sequential growth in sales in 2Q (well supported by order backlog) and the growing contribution of strategic initiatives (starting from Mexico, already in ramp-up phase) is providing strong support to our FY24 projections.

We prefer to wait for another quarter of solid execution before revisiting our assumptions, given the still uncertain macro context and prudent start to the year for **key industry players, not yet projecting any market rebound in FY24**. For these reasons, **we do not apply meaningful changes to our FY estimates**, which are implying +8.6% organic sales (+7.2% in 1Q) and +230bps margin expansion (+300bps in 1Q).


BUY confirmed. Improving visibility/momentum at still compressed multiples

We confirm our BUY rating with a target of €22, based on an average between multiples (11x EV/EBIT 2025 and 13x Adj PE 2025 discounted to 12M from today) and DCF.


The stock trades at 13-10x EV/EBIT and 16-13x Adj. PE 2024-25, multiples compressed in what we expected to be the **initial phase of cyclical recovery of the business** and given the **good prospects for organic growth**, also driven by **company-specific elements** (Mexican/Indian plants ramp-up, Induction launch, Mansfield/PGA integration). SAB historical 1-year forward Adj. PE has been indeed more in the 14-18x range at the bottom/initial part of market recovery cycle.

MAIN FIGURES - EURmn	2021	2022	2023	2024E	2025E	2026E
SALES Adj	263	253	238	274	291	304
Growth	42.4%	-3.9%	-6.0%	15.1%	6.4%	4.2%
EBITDA Adj	54.1	36.3	33.1	44.1	51.5	54.9
Growth	45.9%	-32.9%	-9.0%	33.4%	16.8%	6.6%
EBIT Adj	37.5	19.9	17.5	22.9	29.7	32.5
Growth	86.7%	-47.0%	-11.9%	31.0%	29.6%	9.3%
PBT Adj	29.7	12.2	12.0	19.6	25.3	28.3
Growth	104.6%	-58.9%	-1.8%	63.2%	29.1%	12.1%
Net Income Adj	26.5	22.1	14.2	14.5	18.5	20.7
Growth	87.9%	-16.6%	-35.9%	2.3%	28.0%	11.9%
MARGIN - %	2021	2022	2023	2024E	2025E	2026E
EBITDA Adj Margin	20.6%	14.4%	13.9%	16.1%	17.7%	18.1%
Ebit Adj margin	14.2%	7.9%	7.4%	8.4%	10.2%	10.7%
Pbt Adj margin	11.3%	4.8%	5.0%	7.1%	8.7%	9.3%
Net Income Adj margin	10.1%	8.7%	5.9%	5.3%	6.4%	6.8%
SHARE DATA	2021	2022	2023	2024E	2025E	2026E
EPS Adj - €c	236	196	119	116	149	167
Growth	89.1%	-17.1%	-39.2%	-2.3%	28.0%	11.9%
DPS ord(A) - €c	60.0	0.0	54.0	55.0	56.0	57.0
BVPS	10.8	13.8	14.2	14.8	15.7	16.8
5.15	10.0	13.0	11.2	11.0	15.7	10.0
VARIOUS	2021	2022	2023	2024E	2025E	2026E
Capital Employed	195	245	254	252	253	250
FCF	-0.5	3.4	17.5	16.4	17.9	23.3
CAPEX	23.8	20.9	18.6	15.1	16.0	16.7
Working capital	68.5	78.2	77.0	82.2	89.8	94.2
Trading Working capital	77.4	84.0	82.9	87.5	94.4	98.2
INDEBTNESS	2021	2022	2023	2024E	2025E	2026E
Nfp Adj	-67.6	-84.4	-73.2	-63.6	-52.5	-36.2
D/E Adj	0.55	0.54	0.42	0.35	0.27	0.17
Debt / EBITDA Adj	1.2x	2.3x	2.2x	1.4x	1.0x	0.7x
Interest Coverage	45.9x	21.8x	8.6x	13.2x	11.6x	13.2x
MARKET RATIOS	2021	2022	2023	2024E	2025E	2026E
P/E Ord Adj	10.2x	8.5x	14.6x	16.4x	12.8x	11.4x
PBV	2.2x	1.6x	1.1x	1.3x	1.2x	1.1x
				000	000	
EV FIGURES	2021	2022	2023	2024E	2025E	2026E
EV/Sales	1.3x	1.1x	1.2x	1.1x	1.0x	0.9x
EV/EBITDA Adj	6.3x	7.6x	8.9x	6.9x	5.7x	5.1x
EV/EBIT Adj	9.1x	14.0x	16.8x	13.3x	9.9x	8.6x
EV/CE	1.8x	1.1x	1.2x	1.2x	1.2x	1.1x
REMUNERATION	2021	2022	2023	2024E	2025E	2026E
Div. Yield ord	2.6%	0.0%	3.4%	2.9%	2.9%	3.0%
FCF Yield Adj	-0.2%	1.4%	9.2%	6.9%	7.5%	9.8%
Roce Adj	15.1%	6.8%	5.3%	6.7%	8.6%	9.5%
Source: Company data and Equita SIM estimates						

Source: Company data and Equita SIM estimates







BUSINESS DESCRIPTION

Sabaf (SAB) is one of the world's leading manufacturers of components for household gas cooking appliances (60% of 2023 group sales and a market share of around 50% in Europe and a global share of about 10%), and in the manufacturing of hinges for consumer appliances (30% of 2023 group sales and undisputed worldwide leader with size c2x the second player). The company is also expanding its presence in electronic components (10% of group sales in 2023) made of electronic control boards, timers, display and power supply units for ovens, kitchen hoods, vacuum cleaners, refrigerators and freezers. The company has also developed internally competencies to enter the induction hob segment, with initial sales expected in 2023 and a target to reach a 5% market share in the medium term. The majority of Sabaf's sales consist of original equipment supply.

The group generated 30% of its 2023 revenues in Europe, 26% in Turkey, 20% in North America, 12% in LatAm, 7% in MENA and 4% in APAC. The Group is characterised by a high revenue concentration, with some 50% arising from sales to its ten largest customers.

The Group in the last 5 years made acquisitions to enter the market of **electric components** (10% of 2023 sales) and strengthened its presence in the market of hinges for consumer appliances (30% of 2023 sales).

SAB main production facilities are in Italy, **Brazil and Turkey**. The company is also present in Poland and China and is building additional plants in **India** and **Mexico**.

7-YEAR BUSINESS TRENDS (€ mn)									
	2017	2018	2019	2020	2021	2022	2023		
Adj. SALES	150	151	156	185	263	252	239		
- gas components	141	136	122	130	182	157	143		
- hinges	9	10	24	41	58	69	70		
- electronics	0	4	10	14	22	26	25		
Adj. EBITDA	31.0	30.0	27.0	37.1	54.1	36.3	33.1		
Adj. EBITDA margin	20.6%	19.9%	17.3%	20.1%	20.6%	14.4%	13.8%		
Adj. Net Income	12.4	11.5	8.1	14.1	26.5	22.1	14.2		

Source: Company data

In 2016-2019 SAB set the base for a stronger business diversification, expanding the relation with strategic clients (Whirlpool NA, Electrolux, Mabe), entering in new markets (electronics) and strengthening the presence in hinges. The strategy was led by the CEO Pietro lotti, former head of Interpump Hydraulics. 2020-2021 saw strong growth in sales and margins, thanks to a sharp increase in market demand boosted by higher spending on household appliances during the pandemic and the first contribution of new projects with strategic clients. The spending in household appliances normalized in 2022-23, driving declining organic sales and margins in the industry. 4Q23 was the first quarter with a return to positive organic growth since 2Q22.

Post 2023 reserved capital increase to finance MEC acquisition, Sabaf's largest shareholders are: the Saleri family (18.5% of capital and 24.9% of voting rights) and Quaestio Capital (18.2% of capital and 24.5% of voting rights) due to a loyalty share mechanism for investors keeping the shares for at least 2 years.

STRENGTHS / OPPORTUNITIES	WEAKNESSES /THREATS
- Strong leadership in Europe	- Concentration of revenues with large appliances
- High quality and efficiency, innovation skills	manufacturers
- Direct manufacturing presence in key countries	- Exposure to mature markets (WE), where induction
- Development of new markets and clients	is taking share from gas cooking
- Track record of inorganic expansion	- Volatility of commodity and energy prices
	- Client consolidation

1Q24 was the second quarter in a row of positive organic top-line performance and YoY margin expansion (though not yet at the medium-term high-teens target).

1Q24 was also the first quarter since the start of the market downturn delivering a positive surprise on our expectations in terms of profitability.

SABAF - 1Q 24 - RESULTS									
		EXPEC	TED	REPORTED					
	Q1-23	Q1-24E	YoY gr. %	Q1-24E	YoY gr. %				
Revenues	58.1	69.1	19%	68.9	19%				
Adjusted EBITDA	7.1	10.1	42%	10.6	48%				
Margin	12.3%	14.6%		15.3%	-				
Adj. EBIT	2.9	4.8	68%	5.8	102%				
Margin	5.0%	7.0%	-	8.4%	-				
Adj. net income	1.4	2.7	93%	4.6	225%				
Margin	2.4%	3.9%	-	6.7%	-				
NFP	-86.4	-76.9	-11%	-77.1	n.m.				

Source: Equita SIM estimates and Company data

Sales grew by +19% to € 68.9mn vs. € 69.1mn exp., with organic +7.2% vs. 7.0% expected and M&A adding € 6.8mn vs. € 7.0mn expected. Management thinks SAB has gained market share in 1Q24 across all geographies.

From a geographical standpoint, **EMEA and Turkey showed robust rebounds** (+5% and +9% respectively), NA was up by 90% or we estimate 2% organically. Positive performance was also booked in LatAm (+3%) and Asia (2x on small number, supported by India and China). The only area down YoY was MENA (-7%).

SALES BREAKDOWN BY PRODUCT – FY (€ mn)								
	1Q23	1Q24	YoY change	organic				
Europe	19.8	20.7	5%	5%				
Turkey	16.9	18.4	9%	9%				
North America	6.7	14.7	90%	2%				
South America	7.7	7.0	3%	3%				
Africa and Middle East	5.3	4.9	-7%	-7%				
Asia	1.7	3.4	100%	100%				
Total sales	58.1	69.0	19%	7.2%				

Source: Company data

From a product standpoint, **gas components grew by 12%** (fully organic), **hinges** grew by 37% but decline by **-7% organically** and **electronics rebounded by 13%** (fully organic).

SALES BREAKDOWN BY PRODUCT – 4Q (€ mn)								
	1Q23	1Q24	YoY change	organic				
Gas components	36.2	40.6	12%	12%				
Hinges	15.3	20.9	37%	-7%				
Electronic components	6.6	7.4	13%	13%				
Total sales	58.1	69.0	19%	7.2%				

Source: Company data

Adj. EBITDA jumped by +48% to € 10.6mn vs. € 10.1mn expected. **Adj. EBITDA margin reached 15.3%** (excluding hyperinflation impact, but including start-up costs, no more booked as one-off costs as done in 2023) vs. 14.6% expected and +300bps YoY vs. 12.3% in 1Q23 (+360bps YoY if we include 1Q23 start-up costs in normalized EBITDA, as done in 1Q24).

The bridge in EBITDA compared to 1Q23 (\notin 3.5mn or +300bps in margin from 12.3% to 15.3% in 1Q24 from 12.3% in 1Q23) was the following:

- higher organic **volumes** (€ 1mn) and better productivity (€ 0.8mn)
- better Raw Material costs (€ 1.6mn)
- ... partly offset by higher labour costs in Turkey and Italy.

Adj. EBIT reached € 5.8mn vs. € 4.8mn exp. due to higher EBITDA and lower D&A (not yet affected by amortization of the new Mexican plant and by induction development).

Adj NI more than trebled to € 4.6mn, much higher than our € 2.7mn expectation, benefitting from FX gains and a 22% tax rate (26% expected), on top of EBIT beat.

NFP € -77.1mn, in line with expectations, with € 3.9mn cash absorption vs. FY23 due to working capital (higher receivables due to higher sales and € 6mn lower factoring vs. December). CAPEX were € 2.7mn vs. € 5.4mn in 1Q23, confirming the completion of the major investment program launched in 2022 to ramp-up new capacity in India, Mexico and Turkey and to start-up the induction project.

CASHFLOW STATEMENT (€ mn)								
	1Q23	1Q24						
Cashflow provided by operations	5.9	8.4						
(Increase) decrease in NWC	-0.3	-10.2						
(Purchase of fixed assets)	-5.4	-2.7						
FCF	0.2	-4.5						
(Other net investments)	0.0	0.0						
(Distribution of dividends)	0.0	0.0						
Right issue / (buy-back)	-0.4	0.0						
Others	-1.8	0.6						
(Increase) decrease in net debt	-2.0	-3.9						

Source: Company data

NET WORKING CAPITAL TREND (€ mn)										
	1Q23	% 4xQ Sales	2Q23	% 4xQ Sales	3Q23	% 4xQ Sales	4Q23	% 4xQ Sales	1Q24	% 4xQ Sales
receivables	62.8	27.0%	52.8	23.2%	63.8	26.0%	55.8	23.3%	66.5	27.8%
inventories	65.8	28.3%	59.5	26.2%	67.4	27.5%	62.0	25.9%	63.4	26.5%
payables	-43.9	-18.9%	-45.8	-20.2%	-40.3	-16.4%	-42.5	-17.8%	-44.5	-18.6%
Trade Working Capital	84.7	36.5%	66.5	29.3%	91.0	37.1%	75.3	31.5%	85.4	35.7%

ource: company data

Here below we present the reported and adjusted P&L. The main adjustment is due to the accounting of Turkey as hyperinflationary economy (IAS 29). Start-up costs related to the new plants and induction launch (we estimate around € 0.7mn in 1Q24) are no more excluded from Adj. EBITDA, as done in 2023 (€ 0.35mn in 1Q23).

	Q1 2024	Q1 2023	2024-2023 change	% change	12 MONTHS 2023
Sales revenue Hyperinflation – Turkey Start-up revenue	68,861 137	58,063 84	10,798	+18.6	237,949 1,160 (23)
Normalised revenue	68,998	58,147	10,851	+18.7%	239,086
EBITDA <i>EBITDA %</i> Start-up costs Hyperinflation – Turkey	10,568 15.3 - (15)	6,529 <i>11.2</i> 354 251	4,039	+61.9%	29,612 <i>12.4</i> 2,649 786
Normalised EBITDA Normalised EBITDA%	10,553 15.3	7,134 <i>12.3</i>	3,419	+47.9%	33,047 <i>13.8</i>
EBIT <i>EBIT %</i> Start-up costs Hyperinflation – Turkey	4,973 <i>7.2</i> - 839	1,497 2.6 483 898	3,476	+232.2%	11,062 <i>4.6</i> 3,724 2,710
Normalised EBIT Normalised EBIT%	5,812 <i>8.4</i>	2,878 <i>4.9</i>	2,934	+101.9%	17,496 7.3
Group net result Net result % Start-up costs Hyperinflation – Turkey	4,270 <i>6.2</i> 425	(791) - <i>1.4</i> 438 1,769	5,061	+639.8%	3,103 1.3 3,530 7.521
Normalised result of the Group Normalised result %	4,695	1,416 2,4	3,279	+231.7%	14,154 5.9

Source: SAB press release

2024 OUTLOOK CONFIRMED, WELL SUPPORTED BY CURRENT TRADING

From the call:

- Orders in 2Q were defined as "brilliant", providing comfort on 2024 outlook. Visibility on 2H is limited, as usual, but 2Q will see sequential organic growth (QoQ) and there are no reasons to expect a deterioration of organic performance in 2H, also considering the growing contribution from Mexico (and to a lower extent India and induction).
- Mansfield (acquired in August 2023) a bit impacted by Whirlpool lower sales in NA in 1Q24, but overall performing well and already delivering a 300/400bps improvement in EBITDA margin since the acquisition.
- There is room to expand EBITDA margin going forward, if volumes stay at these levels.
- M&A: no deals expected in 2024, because management focus will be on integration of Mansfield (e.g. new investment to improve productivity) and PGA (e.g. production of boards for induction was insourced to PGA).
- CAPEX: € 2.7mn in 1Q, with € 14-15mn planned for 2024 (€ 15mn exp.)

Overall, **the tone of the call was very supportive**, with 2Q expected to accelerate vs. 1Q (we had flat performance) and message on orders just qualitative but very reassuring.

KEY INDUSTRY PLAYERS STILL PRUDENT ON MARKER RECOVERY

Key listed industry players **Whirlpool and Electrolux reported quite weak numbers for 1Q24**, with sales down due to lower volumes and negative price/mix **but reaffirmed the FY24 market outlook of stability in industry shipments in the main geographical areas.**




Source: Whirlpool and Electrolux 4Q23 presentation


Arcelik highlighted a sequential decrease of market contraction in WE (with some markets like Spain and the UK showing first signs of rebound), while EE has continued to grow both in unit terms and value.



The following chart shows industry shipments in Europe and US over the last 10 years. It is striking to see **Europe entering the 12th consecutive quarter of declining market demand**, an element supporting some market recovery as of 2H24, also due to a likely more favourable trend in interest rates.







Source: Electrolux 1Q24 presentation

ESTIMATES UNCHANGED BUT NOW OFFERING MUCH STRONGER VISIBILITY

The indication on sequential growth in sales in 2Q (well supported by order backlog) and the growing contribution of strategic initiatives (starting from Mexico, already in ramp-up phase) is providing strong support to our FY24 projections. However, we prefer to wait for another quarter of solid execution before revisiting our assumptions, given the still uncertain macro context and prudent start to the year for key industry players, not projecting any market rebound in FY24.

For these reasons, we do not apply meaningful changes to our FY estimates, which are implying +8.6% organic sales (+7.2% in 1Q) and +230bps margin expansion (+300bps in 1Q).

	C	HANGE IN ES	TIMATES (€ mn)			
	2024E	2024E	2025E	2025E	2026E	2026E
	Exp.	Act.	Prev.	Curr.	Prev.	Curr.
Revenues	273.8	273.9	291.2	291.4	303.5	303.7
% chg		0.0%		0.1%		0.1%
Abs chg		0.1		0.2		0.2
Adj. EBITDA	44.1	44.1	51.5	51.5	54.9	54.9
% chg		0.0%		0.1%		0.1%
Abs chg		0.0		0.0		0.1
Adj. EBIT	22.9	22.9	29.7	29.7	32.4	32.5
% chg		0.1%		0.1%		0.2%
Abs chg		0.0		0.0		0.1
Adj. Net income	14.5	14.5	18.5	18.5	20.7	20.7
% chg		0.1%		0.2%		0.2%
Abs chg		0.0		0.0		0.0
Net income	14.5	14.5	18.5	18.5	20.7	20.7
% chg		0.1%		0.2%		0.2%
Abs chg		0.0		0.0		0.0
Adj. EPS (€ cents)	116	116	149	149	166	167
% chg		0.1%		0.2%		0.2%
Abs chg		0.1		0.2		0.3
NFP	-63.9	-63.6	-52.9	-52.5	-36.6	-36.2
% chg		-0.6%		-0.7%		-1.0%
Abs chg		0.4		0.4		0.4
FCF	16.0	16.4	17.9	17.9	23.3	23.3
% chg		2.3%		-0.1%		0.0%
Abs chg		0.4		0.0		0.0
CAPEX	15.1	15.1	16.0	16.0	16.7	16.7
% chg		0.0%		0.1%		0.1%
Abs chg		0.0		0.0		0.0
DPS (€	55.0	55.0	56.0	56.0	57.0	57.0
% chg		0.0%		0.0%		0.0%
Abs chg		0		0		0

Source: Equita SIM estimates

VALUATION CONFIRMED

We confirm our BUY rating with a target of \notin 22, based on 11x EV/EBIT 2025 discounted to 12M from today. The stock trades at 13-9.8x EV/EBIT and 16-13x Adj. PE 2024-25, multiples compressed in what we expected to be the initial phase of cyclical recovery of the business and given the good prospects for organic growth, also driven by company-specific elements (Mexico, India, Induction, Mansfield/PGA integration).

PE MULTIPLE VALUATION		TARGET PRICE SENSITIVITY					
(A) 2025E multiple	13 x	(A) 2025E multiple	11 x	13 x	15 x		
(B) 2025 EPS (€)	1.5	(B) 2025 EPS (€)	1.5	1.5	1.5		
(C) synergies EPS contribution post 2025 (€)	0.1	(C) synergies EPS contribution post 2025 (€)	0.1	0.1	0.1		
(D)=(A)x((B)+(C))) Stock value (€)	21	(D)=(A)x((B)+(C))) Stock value (€)	17	21	24		
(E) Dividends to be cashed-in (€)	1.1	(E) Dividends to be cashed-in (€)	1.1	1.1	1.1		
(F) = (C)+(D) Total stock value (€ PS)	22	(F) = (C)+(D) Total stock value (\in PS)	19	22	25		
(G) Discount (1+Ke)	1.06	(G) Discount (1+Ke)	1.06	1.06	1.06		
(H)=(F)/(G) Target (€ PS)	20	(H)=(F)/(G) Target (€ PS)	18	20	23		
Source: Equita SIM estimates							

EV/EBIT MULTIPLE VALUATION (€ mn)		TARGET PRICE SENSITIVITY (€ mn)				
(A) 2025E multiple	11.0 x	(A) 2025E multiple	9 x	11 x	13 x	
(B) 2025 EBIT	30	(B) 2025 EBIT	30	30	30	
(C) synergies post 2025	1	(C) synergies post 2025	1	1	1	
(D)=(A)x((B)+(C)) EV	336	(D)=(A)x((B)+(C)) EV	275	336	397	
(D) NFP 2025E	-53	(D) NFP 2025E	-53	-53	-53	
(E) minorities	-4	(E) minorities	-4	-4	-4	
(F) Dividends to be cashed-in	14	(F) Dividends to be cashed-in	14	14	14	
(G) = (C)+(D)+(E)+(F) Total stock value	292	(G) = (C)+(D)+(E)+(F) Total stock value	231	292	353	
(H) Discount (1+Ke)	1.06	(H) Discount (1+Ke)	1.06	1.06	1.06	
(I)=(G)/(H) Target (€ PS)	275	(I)=(G)/(H) Target (€ PS)	218	275	333	
(L) shares (mn)	12.4	(L) shares (mn)	12.4	12.4	12.4	
(M)=(I)/(L) Target (€ PS)	22	(M)=(I)/(L) Target (€ PS)	18	22	27	

Source: Equita SIM estimates

The DCF-based valuation leads to a target of \notin 25PS, based on a WACC of 8.7% and perpetual growth of 2.5%.

Assumptions			2024E	2025E	2026E	2027E	2028E	Perpetuity
G	2.5%	Sales	274	291	304	313	322	330
WACC	8.8%	Change %	15.1%	6.4%	4.2%	3.0%	3.0%	2.5%
		EBITDA	44	52	55	57	59	59
		Change %	33.4%	16.8%	6.6%	4.1%	3.0%	0.9%
		Margin	16.1	17.7	18.1	18.3	18.3	18.0
		D&A	-21.2	-21.8	-21.3	-20.3	-20.9	-21.5
		EBIT	23	30	32	37	38	38
		Change %	31.0%	29.6%	9.3%	13.5%	3.0%	3.1%
Valuation (€ mn)		Margin	8.3	8.4	10.2	10.7	11.8	11.8
NPV of FCF (2024-28)	94	Taxes	-6	-8	-9	-10	-10	-10
NPV of Terminal Value	293	EBIT after Tax	17	22	24	27	28	28
Estimated Enterprise Value	387	Change %	31.0%	29.6%	9.3%	13.5%	3.0%	3.1%
2023E NFP	-73	2						
Adjustment to NFP	0	Capex/acquisitions	-15	-16	-17	-20	-21	-21
SAB IM Equity	314	(increase) decrease in NWC	-6	-8	-4	-3	-3	-3
Minorities & Peripheral	-4	Free Cash Flow before minorities	17	20	24	24	24	25
Total Equity								
		Free Cash Flow	17	20	24	24	24	25
Adj. # of shares (mn)	12.4							
		Discount Factor	1.0	1.1	1.1	1.2	1.4	1.4
Target Price (€ PS)	25	PV of FCF	18	19	21	19	18	18

DCF SENSITIVITY ANALYSIS (€ PS)						
Perpetual growth G						
	1.5%	2.5%	3.5%			
8.3%	24	27	32			
8.8%	22	25	28			
9.3%	21	23	25			
	8.3% 8.8%	Perpetual 0 1.5% 8.3% 24 8.8% 22	Perpetual growth G 1.5% 2.5% 8.3% 24 27 8.8% 22 25			

SABAF VALUATION					
	Weight	Target multiple	Valuation (€ PS)		
PE multiple valuation	33%	13x	22		
EV/EBIT valuation	33%	11x	20		
DCF valuation	33%	n.m.	25		
Target price			22		

A confirmation of favourable momentum could support higher multiples over the next few quarters, considering that SAB historical 1-year forward Adj. PE has been more in the 14-18x range at the bottom/initial part of recovery cycle.

STATEMENT OF RISKS FOR SABAF

The main factors that could negatively affect SAB are the following:

- Weaker market demand
- Higher competitive pressures
- Sharp increase in aluminium and steel prices
- Inability to acquire and integrate companies
- Inability to enter new markets
- Inability to protect its product exclusivity
- Development of alternative technologies

P&L - €mn	2021	2022	2023	2024E	2025E	2026E
SALES Rep	263	253	238	274	291	304
Growth	42.4%	-3.9%	-6.0%	15.1%	6.4%	4.2%
EBITDA Rep	54.1	40.1	29.6	44.1	51.5	54.9
Growth	45.9%	-25.9%	-26.2%	49.0%	16.8%	6.6%
Margin	20.6%	15.8%	12.4%	16.1%	17.7%	18.1%
D&A	-16.6	-18.2	-18.5	-21.2	-21.8	-22.5
EBIT Rep	37.5	21.9	11.1	22.9	29.7	32.5
Growth	86.7%	-41.6%	-49.5%	107.2%	29.6%	9.3%
Margin	14.2%	8.6%	4.6%	8.4%	10.2%	10.7%
Net Interest Charges	-1.2	-1.8	-3.4	-3.4	-4.4	-4.1
Financial Expenses	-7.8	-9.7	-11.1	-3.4	-4.4	-4.1
Non Recurrings	0.0	0.0	0.0	0.0	0.0	0.0
PBT Rep	29.7	12.2	-0.1	19.6	25.3	28.3
Growth	104.6%	-58.9%	n.m.	n.m.	29.1%	12.1%
Income Taxes	-5.0	3.0	3.4	-5.1	-6.7	-7.6
Tax rate	16.8%	-24.9%	5643.3%	26.0%	26.6%	26.7%
Minority Interest	-0.8	0.0	-0.2	-1.0	-1.2	-1.2
Discontinued Operations	0.0	0.0	0.0	1.0	1.2	1.2
Net Income Rep	23.9	15.2	3.1	14.5	18.5	20.7
Growth	71.2%	-36.2%	-79.7%	366.6%	28.0%	11.9%
Margin	9.1%	6.0%	1.3%	5.3%	6.4%	6.8%
Net Income Adj	26.5	22.1	14.2	14.5	18.5	20.7
Growth	87.9%	-16.6%	-35.9%	2.3%	28.0%	11.9%
Margin	10.1%	8.7%	5.9%	5.3%	6.4%	6.8%
CF Statement	2021	2022	2023	2024E	2025E	2026E
FFO	41.6	33.5	23.4	36.6	41.5	44.4
Chg. in Working Capital	-18.3	-9.3	12.7	-5.2	-7.6	-4.4
Other chg. in OCF	0.0	0.0	0.0	0.0	0.0	0.0
NCF from Operations	23.2	24.2	36.1	31.4	33.9	40.0
CAPEX	-23.8	-20.9	-18.6	-15.1	-16.0	-16.7
Financial Investments	0.0	-9.8	-21.2	0.0	0.0	0.0
Other chg in investments	0.0	0.0	0.0	0.0	0.0	0.0
NCF from Investments	-23.8	-30.6	-39.8	-15.1	-16.0	-16.7
Dividends paid	-6.2	-6.7	0.0	-6.7	-6.8	-7.0
Capital Increases	0.0	0.2	16.9	0.0	0.0	0.0
Other changes in financing	-4.6	-3.9	-2.0	0.0	0.0	0.0
CHG IN NFP	-11.3	-16.8	11.2	9.6	11.0	16.4

Source: Company data and Equita SIM estimates

INFORMATION PURSUANT TO EU REGULATION 2016/958 supplementing Regulation EU 596/2014 (c.d. MAR)

This publication has been prepared by the following financial analyst(s) on behalf of EQUITA SIM SpA (licensed to practice by CONSOB resolution no. 11761 of December 22nd 1998 and registered as no. 67 in the Italian central register of investment service companies and financial intermediaries) to which he/she/they is/are bound by an employment contract: Domenico Ghilotti

In the past EQUITA SIM has published studies on Sabaf

EQUITA SIM is distributing this publication via e-mail to more than 900 qualified operators and to unqualified operators via Borsa Italiana website on Monday, 20 May 2024 at 02:42 PM.

The prices of the financial instruments shown in the report are the closing prices of the date indicated in the first page stock data table.

EQUITA SIM intends to provide continuous coverage of the financial instrument forming the subject of the present publication, with a semi-annual frequency and, in any case, with a frequency consistent with the timing of the issuer's periodical financial reporting and of any exceptional event occurring in the issuer's sphere of activity.

The information contained in this publication is based on sources believed to be reliable. Although EQUITA SIM makes every reasonable endeavour to obtain information from sources that it deems to be reliable, it accepts no responsibility or liability as to the completeness, accuracy or exactitude of such information. If there are doubts in this respect, EQUITA SIM clearly highlights this circumstance. The most important sources of information used are the issuer's public corporate documentation (such as, for example, annual and interim reports, press releases, and presentations) besides information made available by financial service companies (such as, for example, Bloomberg and Reuters) and domestic and international business publications. It is EQUITA SIM's practice to submit a pre-publication draft of its reports for review to the Investor Relations Department of the issuer forming the subject of the report, solely for the purpose of correcting any inadvertent material inaccuracies. This note has been submitted to the issuer.

The recommendation was produced using proprietary Excel models that are stored on company servers. The models are backed up at the end of each month.

EQUITA SIM has adopted internal procedures able to assure the independence of its financial analysts and that establish appropriate rules of conduct for them.

Furthermore, it is pointed out that EQUITA SIM SpA is an intermediary licensed to provide all investment services as per Italian Legislative Decree no. 58/1998. Given this, EQUITA SIM might hold positions in and execute transactions concerning the financial instruments covered by the present publication, or could provide, or wish to provide, investment and/or related services to the issuers of the financial instruments covered by this publication. Consequently, it might have a potential conflict of interest concerning the subject of the present publication.

Equita SIM S.p.A. performs or has performed in the last 12 months the role of specialist for financial instruments issued by Sabaf. Equita SIM S.p.A. performs or has performed in the last 12 months the role of intermediary in charge of the execution of the buy back plan approved by the shareholders' meeting of Sabaf. Equita SIM S.p.A. provides or has provided in the last 12 months corporate finance services to Sabaf S.p.A. or to a company of the same group.

In addition, it is also pointed out that, within the constraints of current internal procedures, EQUITA SIM's directors, employees and/or outside professionals might hold long or short positions in the financial instruments covered by this publication and buy or sell them at any time, both on their own account and that of third parties.

Research Division management alone determines the remuneration of the analysts who produced the publication, and their remuneration is not linked to Equita SIM's Investment Banking transactions. It is linked to Equita SIM's total revenue, which includes the revenue of the Investment Banking and Sales & Trading Divisions.

For more details on the policies and principles designed to ensure the integrity and independence of Equita SIM analysts, please refer to the policy on organizational mechanisms of the Research activity available at <u>www.equita.eu</u> on the "Legal notices" section.

The recommendations to BUY, HOLD and REDUCE are based on Expected Total Return (ETR – expected absolute performance in the next 12 months inclusive of the dividend paid out by the stock's issuer) and on the degree of risk associated with the stock, as per the matrix shown in the table. The level of risk is based on the stock's liquidity and volatility and on the analyst's opinion of the business model of the company being analysed. Due to fluctuations of the stock, the ETR might temporarily fall outside the ranges shown in the table.

EXPECTED TOTAL RETURN FOR THE VARIOUS CATEGORIES OF RECOMMENDATION AND RISK PROFILE

RECOMMENDATION/RATING	Low Risk	Medium Risk	High Risk
BUY	ETR >= 10%	ETR >= 15%	ETR >= 20%
HOLD	-5% <etr< 10%<="" td=""><td>-5% <etr< 15%<="" td=""><td>0% <etr< 20%<="" td=""></etr<></td></etr<></td></etr<>	-5% <etr< 15%<="" td=""><td>0% <etr< 20%<="" td=""></etr<></td></etr<>	0% <etr< 20%<="" td=""></etr<>
REDUCE	ETR <= -5%	ETR <= -5%	ETR <= 0%

The methods preferred by EQUITA SIM to evaluate and set a value on the stocks forming the subject of the publication, and therefore the Expected Total Return in 12 months, are those most commonly used in market practice, i.e. multiples comparison (comparison with market ratios, e.g. P/E, EV/EBITDA, and others, expressed by stocks belonging to the same or similar sectors), or classical financial methods such as discounted cash flow (DCF) models, or others based on similar concepts. For financial stocks, EQUITA SIM also uses valuation methods based on comparison of ROE (ROEV – return on embedded value – in the case of insurance companies), cost of capital and P/BV (P/EV – ratio of price to embedded value – in the case of insurance companies).

Ord SAB IM MOST RECENT CHANGES IN RECOMMENDATION AND/OR IN TARGET PRICE: Target Price Date Rec. Risk Comment January 15, 2024 Buy 22.00 High change in estimates/valuation October 25, 2023 Buy 20.00 High July 17, 2023 Buy 21.00 High change in estimates/valuation Hold May 12, 2023 19.00 High

DISCLAIMER

The purpose of this publication is merely to provide information that is up to date and as accurate as possible. The publication does not represent to be, nor can it be construed as being, an offer or solicitation to buy, subscribe or sell financial products or

instruments, or to execute any operation whatsoever concerning such products or instruments. EQUITA SIM does not guarantee any specific result as regards the information contained in the present publication, and accepts no responsibility or liability for the outcome of the transactions recommended therein or for the results produced by such transactions. Each and every investment/divestiture decision is the sole responsibility of the party receiving the advice and recommendations, who is free to decide whether or not to implement them. Therefore, EQUITA SIM and/or the author of the present publication cannot in any way be held liable for any losses, damage or lower earnings that the party using the publication might suffer following execution of transactions on the basis of the information and/or recommendations contained therein. The estimates and opinions expressed in the publication may be subject to change without notice.

te estimates and opinions expressed in the publication may be subject to change without notice.

EQUITY RATING DISPERSION AS OF MARCH 31, 2024 (art. 6, par. 3 Delegated Regulation (EU) 2016/958 of 09 March 2016)					
	COMPANIES COVERED	COMPANIES COVERED WITH BANKING RELATIONSHIP			
BUY	56.3%	65.8%			
HOLD	42.4%	32.9%			
REDUCE	0.0%	0.0%			
NOT RATED	1.3%	1.4%			

The list of all conflicts of interest, rating dispersion, last 12 months recommendation made by Equita SIM's analysts and other important legal disclaimers are available on www.equita.eu in the "Legal notices" section.

This document has been provided to you solely for informational purposes and may not be reproduced or distributed, directly or indirectly, to any other person, nor may it be published, wholly or in part, for any reason, without EQUITA SIM's specific authorisation. By accepting this document, you agree to comply with the limitations indicated above.

For Entities and Clients in the United Kingdom

Equita is registered as a UK's "Overseas Persons Exclusion" ("**OPE**"): this means that Equita has not established an actual or deemed permanent place of business in the UK. Equita is not a member of the "Financial Conduct Authority" and Research Analysts and Research Reports must comply with requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered to UK "investment professionals" and "high net worth companies" and the investment to which it relates is available only to such persons and that any other person(s) should not act or rely upon it.

For Entities and Clients in the United States

Equita is not registered as a broker-dealer with the U S Securities and Exchange Commission, and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Equita is not a member of the Financial Industry Regulatory Authority. It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest.

This research report is only being offered to Major U S Institutional Investors and is not available to, and should not be used by, any U S person or entity that is not a Major U S Institutional Investor. Equita can not and will not accept orders for the securities covered in this research report placed by any person or entity in the United States. Orders should be placed with our correspondent, Auerbach Grayson & Co. 212-557-4444.